fimaVACC


Dette er hentet fra prospektet og burde leses, har sagt det før men kan godt si det igjen.

Her kan det smelle noe så inn i granskauen.

The competitive landscape for PCI Biotech’s fimaVACC technology
Therapeutic cancer vaccination has been a growing field with a substantial development pipeline and high
expected market growth35. Several late stage failures due to poor efficacy have however highlighted the need
for improved vaccination technologies with increased immune responses36. fimaVACC is a novel Cytotoxic T-Cell
(CTL) induction technology with an innovative mode of action through CTL induction by enhanced MHC class I
antigen presentation in dendritic cells and macrophages. CTL induction is a key factor for the efficacy of
therapeutic vaccines. PCI Biotech has compelling pre-clinical data showing significant immune-potentiating
effects, which in addition works in strong synergy with other state-of-the-art vaccine technologies in clinical
development, and translates into therapeutic effect in disease models. Initial data from the ongoing Phase I study
in healthy volunteers on overall T-cell responses indicate that vaccination with well-tolerated doses of fimaVACC
enhance cellular immune responses important for therapeutic effect of vaccines. The data also suggest that
fimaVACC trigger early T-cell responses and provide high response rates, which are two highly sought-after
features of vaccination platforms.

Mulige bruksområder:

1. Fight against cancer with immunotherapy.
2. Therapeutic and prophylactic vaccination for other important diseases.
3. Treatment of chronic viral diseases.
4. Tuberculosis.
5. Malaria.
6. Prophylactic vaccines for important infectious diseases.

++++ there are also many other potential target diseases for fimaVACC based prophylactic vaccination.


The active ingredient in fimaVACC (fimaporfin; TPCS2a) is a stable small molecule with broad applicability. All these
attributes makes the fimaVACC technology a potential future important player in the fight against cancer with
immunotherapy. In addition to the use in therapeutic vaccination for cancer, fimaVACC has the potential to be
used for both therapeutic and prophylactic vaccination for other important diseases. E.g., fimaVACC is very well
suited for therapeutic vaccination for the treatment of chronic viral diseases (e.g. Hepatitis B), and possibly also
for therapeutic vaccination for tuberculosis. Furthermore, the fimaVACC technology also has a clear potential to
contribute to the development of new prophylactic vaccines for important infectious diseases lacking effective
vaccines. Prominent examples are malaria and tuberculosis, but there are also many other potential target
diseases for fimaVACC based prophylactic vaccination.

Helt rått :)


Status på hva dem holder på med ang fimaVACC hos PCIB nå :)

The Company is actively working on business development activities to enter into new value-creating
collaborations. Pre-clinical data has convincingly demonstrated that the fimaVACC technology not only provides
effective cytotoxic T-cell induction, but can also elicit strong enhancement of all other important immune
responses. A successful clinical validation of these preclinical results is an important value-creating step for the
fimaVACC programme.
Redigert 19.09.2018 kl 12:12 Du må logge inn for å svare
fabian2
19.09.2018 kl 13:37 1255

Convinsignly demonstrated….he-he….egentlig er det jo dette vi også venter på skal publiseres , dette går veien.!!!!…....la det smelle slik at granskauen blir ryddet så åpen at VTOL-fly kan lande uten problemer :)
heilo888
19.09.2018 kl 14:27 1191

Dette bør være bekreftelse nok!
De kan umulig uttalt seg på denne måten uten at det blir suksess!
AnnaLyst
19.09.2018 kl 14:45 1158

Ting tar tid. Mens vi venter på endelige beviser, stiger andre papirer 50%
fabian2
19.09.2018 kl 15:39 1079

…………...Geparden maler så høyt at huset rister...….....spøk til side , geparder maler faktisk veldig høyt ( har bodd i Pretoria)
Panis
19.09.2018 kl 19:26 973

Tror deg fabian2, men er det noen som vet hvor det er blitt av gepard1, han var jo et positivt innslag her på trådene.
fabian2
19.09.2018 kl 20:29 866

Det er alltid noen "andre papirer" som stiger 50%.....men det ettertrykkelig bevist at "vanlige småtradere" gjør det økonomisk litt dårligere enn de som sitter long…..hadde det bare vært så enkelt , hadde vi alle vært rike/rikere..... men selvsagt er det spennende for de som prøver seg på 50% stadig vekk....litt moro er det jo også.....så har man noe å holde på med....
fabian2
19.09.2018 kl 23:25 708

Startinnlegget er nok for vitenskapelig og seriøst til at Donald våger seg inn her , dette skjønner han ikke en "dritt" av ,...………... og så er det jo fint med en anderfri tråd , da :)

Styreleder Hans Peter Bøhn full tegner for 1,200,000 kroner, som dere kan lese nedenfor så er han financial analyst in Fondsfinans and From 2012 he has been manager of the nonprofit "Svanhild og Arne Musts Fond for Medisinsk Forskning.(google gjerne Arne Must)

Som jeg har nevnt tidligere så var nok denne emisjonen ønsket av de største aksjonærene fordi dem ser den enorme verdiøkningen PCIB kan få de neste årene.



Hans Peter Bøhn (born 1955), Chairman Dr. Bøhn is a Norwegian citizen with a medical degree. He started his pharmaceutical industry career as medical adviser in Nycomed Imaging. Over the ensuing 12 years he gained broad experience from management positions in the pharmaceutical industry within drug safety, international marketing and operations and clinical research as well as gaining a post-graduate Diploma of Pharmaceutical Medicine. After the years in the industry he joined Fondsfinans as a financial analyst covering the life science sector. From 2012 he has been manager of the nonprofit "Svanhild og Arne Musts Fond for Medisinsk Forskning" as well as serving as an independent adviser to among others the Research Council of Norway, the Norwegian Cancer Society, Innovation Norway, Oslo Cancer Cluster as well as a number of biotech start-up companies. He has been a Board member of PCI Biotech Holding ASA since 2015.






Underwriter Address NOK underwritten
Nyenburg Holding B.V. Beursplein 5, 1012 JW Amsterdam, the Netherlands 99 000 000
MP Pensjon PK Lakkegata 23, 0187 Oslo, Norway 90 000 000
Fondsavanse AS Haakon VIIs gate 2, 0161 Oslo, Norway 39 500 000
Norda ASA Stortingsgata 28, 0161 24 000 000
Verdipapirfondet First Globalt Fokus Bolette Brygge 1, 0252 Oslo, Norway 24 000 000
Myrlid AS Strandkaien 16, 5013 Bergen 20 000 000
Kistefos AS Dokkveien 1, 0250 Oslo, Norway 15 000 000
Altitude AS Holmenkollveien 133A, 0787 Oslo, Norway 12 000 000
Veslik AS c/o Koppang, Torjusbakken 19D, 0378 Oslo 7 500 000
Storebrand Norge Indeks Professor Kohts vei 9, 1366 Lysaker 7 500 000
TD Veen AS Eiganesveien 95, 4009 Stavanger, Norway 7 500 000
Wenaas Kapital AS Furulundvegen 7, 6386 Måndalen, Norway 6 000 000
Radiumhospitales Forskningsstiftelse Ullernchausséen 64, 0379 Oslo 5 000 000
L1 Capital Global Opportunities Master Fund
161A Shedden road, 1 Artillery Court, PO Box 10085, Grand Cayman KY1-1001, Cayman Islands
2 000 000
Stocken Invest AS* Stjerneveien 13, 0779 Oslo 1 000 000
Redigert 20.09.2018 kl 08:51 Du må logge inn for å svare